Effector and Central Memory Poly-Functional CD4+ and CD8+ T Cells are Boosted upon ZOSTAVAX® Vaccination by Janet J. Sei et al.
October 2015 | Volume 6 | Article 5531
Original research
published: 29 October 2015
doi: 10.3389/fimmu.2015.00553
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Lee Mark Wetzler, 
Boston University School of 
Medicine, USA
Reviewed by: 
Aaron T. Irving, 
National University of Singapore, 
Singapore 
Tatsuo Suzutani, 
Fukushima Medical University School 
of Medicine, Japan
*Correspondence:
Kalpit A. Vora 
kalpit.vora@merck.com
†Janet J. Sei and Kara S. Cox have 
contributed equally to this work.
Specialty section: 
This article was submitted to 
Immunotherapies and Vaccines, 
a section of the 
journal Frontiers in Immunology
Received: 15 July 2015
Accepted: 16 October 2015
Published: 29 October 2015
Citation: 
Sei JJ, Cox KS, Dubey SA, 
Antonello JM, Krah DL, Casimiro DR 
and Vora KA (2015) Effector and 
central memory poly-functional CD4+ 
and CD8+ T cells are boosted upon 
ZOSTAVAX® vaccination. 
Front. Immunol. 6:553. 
doi: 10.3389/fimmu.2015.00553
effector and central memory  
poly-functional cD4+ and cD8+ 
T cells are boosted upon ZOsTaVaX® 
vaccination
Janet J. Sei1† , Kara S. Cox2† , Sheri A. Dubey2 , Joseph M. Antonello2 , David L. Krah1 , 
Danilo R. Casimiro2 and Kalpit A. Vora2*
1 Merck Research Laboratories, Department Vaccine Analytical Development, Merck & Co., Inc., Kenilworth, NJ, USA, 
2 Merck Research Laboratories, Department of Infectious Diseases and Vaccines, Merck & Co., Inc., Kenilworth, NJ, USA
ZOSTAVAX® is a live attenuated varicella-zoster virus (VZV) vaccine that is licensed for the 
protection of individuals ≥50 years against shingles and its most common complication, 
postherpetic neuralgia. While IFNγ responses increase upon vaccination, the quality of 
the T cell response has not been elucidated. By using polychromatic flow cytometry, 
we characterized the breadth, magnitude, and quality of ex vivo CD4+ and CD8+ T 
cell responses induced 3–4 weeks after ZOSTAVAX vaccination of healthy adults. We 
show, for the first time that the highest frequencies of VZV-specific CD4+ T cells were 
poly-functional CD154+IFNγ+IL-2+TNFα+ cells, which were boosted upon vaccination. 
The CD4+ T cells were broadly reactive to several VZV proteins, with immediate early 
(IE) 63 ranking the highest among them in the fold rise of poly-functional cells, followed 
by IE62, gB, open reading frame (ORF) 9, and gE. We identified a novel poly-functional 
ORF9-specific CD8+ T cell population in 62% of the subjects, and these were boosted 
upon vaccination. Poly-functional CD4+ and CD8+ T cells produced significantly higher 
levels of IFNγ, IL-2, and TNFα compared to mono-functional cells. After vaccination, a 
boost in the expression of IFNγ by poly-functional IE63- and ORF9-specific CD4+ T cells 
and IFNγ, IL-2, and TNFα by ORF9-specific poly-functional CD8+ T cells was observed. 
Responding poly-functional T cells exhibited both effector (CCR7−CD45RA−CD45RO+), 
and central (CCR7+CD45RA−CD45RO+) memory phenotypes, which expressed com-
parable levels of cytokines. Altogether, our studies demonstrate that a boost in memory 
poly-functional CD4+ T cells and ORF9-specific CD8+ T cells may contribute toward 
ZOSTAVAX efficacy.
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inTrODUcTiOn
Herpes zoster (HZ) or shingles is a debilitating disease characterized by a vesicular rash, with the 
most common complication being postherpetic neuralgia (PHN). PHN is a constant and severe 
pain that develops after clearance of the cutaneous outbreak and can last for several years, thereby 
contributing to the high morbidity of affected individuals (1). HZ is caused by reactivation of 
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latent varicella-zoster virus (VZV) from the sensory ganglia (2). 
Immune responses generated during primary VZV infection 
(chickenpox) have been shown to prevent the reactivation of 
latent VZV (3, 4). However, the incidence of HZ is strongly associ-
ated with advancing age (5, 6). Several investigations have shown 
that T cell-mediated immune responses decline with increasing 
age and during immunosuppression, resulting in reactivation of 
VZV (6–11). However, the levels of anti-VZV antibodies remain 
relatively stable with increasing age (6, 12, 13), demonstrating 
that the humoral immune response may not be sufficient for the 
prevention of HZ. Several studies have reported the induction of 
VZV-specific CD4+ and CD8+ T cells (14–20), with CD4+ T cells 
dominating the memory response (18, 19, 21–23).
The HZ vaccine (ZOSTAVAX®) is a live attenuated Oka/
Merck VZV vaccine indicated for the prevention of HZ and its 
complications in individuals 50 years and older and is approved 
in many countries around the world. ZOSTAVAX reduced the 
incidence of HZ by 69.8% among people aged 50–59 years (24) 
and diminished PHN by 66.5% in people ≥60  years old (25). 
ZOSTAVAX vaccination led to a fold rise in VZV antibody levels 
(13, 26, 27) and a fold increase in VZV-specific effector memory 
and IFNγ-producing cells (9, 13, 26).
The VZV antigens that are known to induce T cell-mediated 
immune responses include structural glycoproteins gB, gC, gE, 
gH, gI, immediate early (IE) 4, IE62, and IE63 proteins and open 
reading frame (ORF) 10 tegument protein (14–20). However, 
the aforementioned studies focused on individual set(s) of viral 
proteins (single or limited numbers of proteins in each study). 
Hence, a comprehensive analysis of the immunodominant T 
cell antigens involved in protection against HZ, and following 
ZOSTAVAX vaccination warrants further investigation. To this 
end, Laing et  al. showed that the diversity of the VZV-specific 
CD4+ T cell repertoire increases after ZOSTAVAX vaccina-
tion (28). A month after vaccination, the authors observed an 
increase in CD4+ T cells that were reactive to glycoproteins (gI, 
gE, and gH), IE proteins (IE63 and IE62), tegument proteins 
(ORF4, ORF9, ORF10, and ORF12), capsid proteins (ORF40 and 
ORF41), and enzymes (ORF18, ORF36, ORF37, and ORF59) 
(28). However, the continuous antigenic stimulation required 
to establish VZV-reactive T cell lines could lead to a sampling 
bias as antigen-specific T cells with the highest frequencies may 
be over-represented. Consequently, we sought to investigate the 
ex vivo (with minimal in vitro manipulation) VZV-specific T cell 
responses induced upon ZOSTAVAX vaccination. Moreover, the 
quality of the T cell response as represented by poly-functionality, 
cytokine expression, and memory phenotype has been shown 
to correlate with vaccine efficacy for other pathogens: hence, 
we investigated whether these responses were induced upon 
ZOSTAVAX vaccination.
Our results independently confirm the data from Laing et al. 
(28) that ZOSTAVAX vaccination leads to broad T cell responses. 
We further demonstrate, for the first time that the highest 
frequencies of memory VZV-specific CD4+ T cells in older 
subjects express four functions (CD154+IFNγ+IL-2+TNFα+). 
Upon vaccination, there was a fold increase in the frequency 
of antigen-specific poly-functional CD4+ T cells. Of the VZV 
antigens assessed, IE63 was dominant in stimulating the highest 
fold rise in the frequency of CD154+IFNγ+IL-2+TNFα+ CD4 T 
cells after vaccination. In 62% of the subjects, we identified a 
novel poly-functional CD8+ T cell population that was reactive 
to ORF9 protein and was boosted upon vaccination. On a per-cell 
basis, poly-functional CD4+ and CD8+ T cells expressed ~10× 
higher levels of IFNγ, IL-2, and TNFα than mono-functional 
T cells. After vaccination, we observed statistically significant 
increases in the expression of IFNγ by IE63- and ORF9-specific 
poly-functional CD4+ T cells, and IFNγ, IL-2, and TNFα expres-
sions by poly-functional ORF9-specific CD8+ T cells. Lastly, 
phenotypic characterization of antigen-specific memory T cells 
demonstrated that they belonged to both central and effector 
populations. Based on our findings, we hypothesize that IE63 
and ORF9 proteins are key VZV antigens required for protective 
responses following ZOSTAVAX vaccination.
MaTerials anD MeThODs
Peptide Design
Sequences for all antigens except IE62 are from VZV parental Oka 
strain accession number AB097933.1 (29). The sequence for IE62 
is from the VZV vaccine Oka strain accession number AB097932.1 
(29). Synthetic peptides (JPT, Germany) were synthesized as 
15-mers overlapping by 11 amino acids, with >70% purity. The 
majority of impurities in synthetic peptide preparations result 
from the formation of peptides with shorter sequences compared 
to the parental target sequence. These truncated sequences do not 
cause non-specific stimulation because they are of the same amino 
acid sequence. Peptide pools were limited to a maximum of 120 
sequences per pool. For larger proteins, we generated two or three 
peptide pools: gB-11–439, gB-2429–743, gE-11–319, gE-2309–623, IE62-11–443, 
IE62-2433–875, IE62-3865–1,310, ORF19-11–96, ORF19-297–191, ORF29-11–
407, ORF29-2397–803, and ORF29-3793–1,199. Lyophilized peptides were 
solubilized in dimethyl sulfoxide (DMSO, Sigma, St. Louis, MO, 
USA) at 20–50 mg/ml and pooled within each protein so that the 
concentration of each peptide in the pool was 400 μg/ml. Peptide 
pools were stored at −70°C in small aliquots to limit freezing and 
thawing cycles. Consistent with clinically validated assays used to 
quantify antigen-specific responses after vaccination, DMSO was 
used as a negative control (30–34). VZV lysate was generated by 
propagating VZV Oka/Merck vaccine strain in human embryonic 
lung fibroblasts MRC5 cell line. Infected cells were harvested upon 
observation of cytopathic effect, lysed by sonication, and UV 
treated to inactivate the virus. Prior to UV irradiation, the titer of 
the VZV stock was determined by plaque reduction assay. VZV 
lysate was aliquoted and cryopreserved at −70°C. For VZV lysate-
specific responses, MRC5 lysate was used as a negative control.
human subjects
The Merck Institutional Review Board approved the human 
studies, and all subjects provided written informed consent. 
Merck employees who requested ZOSTAVAX vaccination were 
approached about volunteering for this study. Twenty-one subjects 
(12 male and nine female) between 55 and 65 years with a history 
of chickenpox were vaccinated with ZOSTAVAX (Merck Research 
Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA). Blood was 
drawn from the subjects prior to vaccination and 3–4 weeks after 
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vaccination. The selection of this time point was based on several 
of the clinical trial protocols that led to the licensure of ZOSTAVAX 
(13, 26). This time point was also independently shown to be a 
peak response time for T cell responses by Laing et al. (28).
Whole Blood stimulation and cytokine 
release assay
Whole blood was collected in sodium heparin vacutainer tubes 
and used for peptide, MRC5 lysate, and VZV lysate stimulation 
within 2  h of the blood draw. For each stimulation condition, 
1  ml of blood was incubated with a final concentration of 
2.5 μg/ml of each peptide within a pool. A matching volume of 
DMSO was used as a negative control sample for each subject. 
Blood was incubated at 37°C for 24 (±2)  h. Blood tubes were 
then centrifuged at 900 × g for 10 min to separate the plasma. 
Plasma was harvested, aliquoted, and stored at −70°C until 
the time of the assay. The plasma was tested for cytokines with 
electrochemiluminescent cytokine assay kits from Meso Scale 
Discovery (Rockville, MD, USA) [Human Pro-Inflammatory-4 I 
Plex ultrasensitive kit (catalog number K15009C-2) and Human 
TH1/TH2 7-Plex ultrasensitive kit (catalog number K15011C-2)] 
according to the manufacturer’s instructions. Plates were read on 
an MSD sector Imager 2400 and the picogram per milliliter of 
each cytokine was calculated with MSD software four-paramater 
fit curve. Non-stimulated (background) cytokine levels were 
subtracted from all stimulated sample results.
PBMc isolation
PBMC were isolated and cryopreserved as previously described 
(35). Frozen PBMC were thawed in complete RPMI-1640 
(Invitrogen), washed and rested overnight in a 37°C/5% CO2 
incubator. Complete RPMI-1640 contains 55 μM 2-mercaptoe-
thanol (Invitrogen), 10 mM HEPES buffer (Invitrogen), 2 mM 
l-glutamine (Invitrogen), 1 mM MEM sodium pyruvate solution 
(Invitrogen), 1× penicillin–streptomycin solution (Invitrogen), 
and 10% heat-inactivated FBS.
antigen stimulation and intracellular 
cytokine staining assays
The OMIP-014-validated assay (33) was adapted for our stud-
ies. Rested PBMC at 1 ×  106 PBMC/well were incubated with 
peptide pools at a final concentration of 2 μg/ml per peptide for 
5.5 h in a 37°C/5% CO2 incubator, in the presence of 1.25 μg/ml 
anti-CD28 (BD Biosciences, San Jose, CA, USA) and anti-CD49d 
(BD Biosciences) costimulatory antibodies. Brefeldin A (Sigma) 
and monensin (Sigma) both at 5 μg/ml final concentrations were 
added after the initial 30 min of incubation. As positive controls, 
PBMC were stimulated with a predetermined titer of VZV Oka 
lysate and staphylococcal enterotoxin B (SEB: 3  μg/ml, Sigma). 
Negative controls cells were treated with DMSO and uninfected 
MRC5 cell lysate. Following incubation, 20 μl of 20 mM EDTA 
(Sigma) was added, and the 96-well plate was transferred to 4°C 
overnight. Overnight incubation with EDTA yielded similar stain-
ing patterns as when cells were stimulated and stained in 1 day.
The next day, cells were washed with 1× PBS and stained with 
LiveDead Violet kit (Invitrogen) for 20 min at room temperature. 
Cells were washed with FACS wash [1× PBS + 1% FBS + 0.01% 
sodium azide (Sigma)], permeabilized, and fixed in BD cytofix/
cytoperm (BD Biosciences) for 20  min at 4°C. PBMC were 
stained with a cocktail of the following antihuman monoclonal 
conjugated antibodies for 30  min at room temperature: CD3-
ECD (clone UCHT1, Beckman Coulter, Brea, CA, USA), CD8-
PerCP-Cy5.5 (clone SK1, BD Biosciences), CD4-APC-Alexafluor 
750 (clone 13B8.2, Beckman Coulter), IL-2-APC (clone 534.111, 
BD Biosciences), IFNγ-BV500 (clone B27, BD Biosciences), 
TNFα-PE-Cy7 (clone Mab11, BD Biosciences), Perforin-FITC 
(clone B-D48, Cell Sciences, Canton, MA, USA), CD154-PE-Cy5 
(clone TRAP1, BD Biosciences), and IL-10-PE (clone JES3-19F1, 
BD Biosciences). After washing with FACS wash, the cells were 
resuspended in BD-stabilizing fix (BD Biosciences) until flow 
cytometric analysis.
For staining of memory markers and cytokines, the cells were 
incubated with the following antihuman antibodies for 45 min 
at 4°C, prior to permeabilization and fixation: CCR7-FITC 
(clone G043H7, Biolegend, San Diego, CA, USA), CD45RO-PE 
(clone UCHL1, eBiosciences, San Diego, CA), and CD45RA-
Brilliant Violet 605 (clone HI100, Biolegend). The protocol 
described earlier was then followed with a cocktail of CD3-ECD, 
CD8-PerCP-Cy5.5, CD4-APC-Alexafluor 750, IL-2-APC, 
IFNγ-BV500, TNFα-PE-Cy7, and CD154-PE-Cy5.
Flow cytometric analysis
Samples were analyzed on an LSR II (BD Biosciences), after 
instrument standardization and characterization by using the BD 
Cytometer Setup and Tracking (CS&T) software and BD™ CS&T 
beads (BD Biosciences). Compensation was performed using the 
BD FACS Diva software (BD Biosciences) based on OneComp 
beads (eBiosciences) stained for each individual antibody, and 
ArC™ Amine Reactive Compensation Bead Kit (Invitrogen) for 
viability dye staining. Between 400,000 and 800,000 events were 
collected for each sample. Analysis was performed using FlowJo 
software v9.8.2 (TreeStar Inc., Ashland, OR, USA). DMSO back-
ground levels were subtracted from peptide-stimulated samples, 
and MRC5 lysate was subtracted from VZV lysate.
Presentation analysis of antigen-specific heterogeneous T cell 
distribution was performed using the Simplified Presentation 
of Incredibly Complex Evaluations’ program version 5.35, 
downloaded from <http://exon.niaid.nih.gov/spice> (36). The 
number of antigen-specific T cells was calculated by multiplying 
the frequency of cells producing cytokines by 106 and dividing 
this value by the frequency of cells in the lymphocyte gate. In 
cases where the background had higher events than the positive, 
resulting in negative values, these were corrected to 1 to allow 
calculation of fold rise.
statistical analysis
Differences in cytokine levels prior to and following ZOSTAVAX 
administration in the 21 subjects were assessed for alternative 
peptide pools using an Exact Wilcoxon’s Signed Rank Test. The 
analyses were performed using StatXact (Cambridge, MA, USA) 
version 4.0.1 for Windows NT. The Exact Wilcoxon’s Signed Rank 
Test is appropriate for identifying a statistically significant increase 
in T cell responses after vaccination, relative to responses before 
TaBle 2 | ranking of VZV antigens stimulating poly-functional cD4+ T cells.
4+ functions (cD154+iFnγ+il-2+TnFα+) 3+ functions (cD154−iFnγ+il-2+TnFα+)
VZV antigen geometric mean fold rise One-sided P-value VZV antigen geometric mean fold rise One-sided P-value
IE63 3.66 <0.0001 IE62-2 2.61 <0.0001
IE62-3 2.25 0.0001 IE62-3 3.50 0.0001
gB-1 2.73 0.0005 ORF9 3.03 0.0001
VZV lysate 2.43 0.0005 gE-1 3.09 0.0002
ORF9 2.64 0.0011 gB-2 2.42 0.0009
gE-1 2.24 0.0012 IE62-1 1.75 0.0040
IE62-1 2.40 0.0020 IE63 2.28 0.0060
IE62-2 2.21 0.0036 gE-2 2.25 0.0101
gE-2 1.95 0.0064 gB-1 2.75 0.0107
gB-2 2.02 0.0134 VZV lysate 2.09 0.0198
P values were calculated using an Exact Wilcoxon’s Signed Rank Test.
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vaccination in the same subject. The purpose of the analysis was 
to provide a metric for the rank ordering of the boost in response 
across the set of different antigens. The one-sided P values from 
the Exact Wilcoxon’s Signed Rank Test serve as that metric. These 
analyses are summarized in Tables 1 and 2. Cytokine expression 
levels in poly-functional and mono-functional cells prior to and 
following ZOSTAVAX vaccination were statistically compared by 
two-tailed paired Student’s t-test performed using Prism software 
(GraphPad, La Jolla, CA, USA). Significant differences were iden-
tified by P values: not significant P ≥ 0.05, *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, and ****P ≤ 0.0001.
resUlTs
selection of VZV antigens
Naturally acquired CMV infection elicits broad and strong T 
cell responses with 151 out of 231 ORF being immunogenic 
against CD4 and/or CD8 T cells (37). Immunogenicity was 
TaBle 1 | hierarchy of VZV antigens stimulating iFnγ, il-2, and TnFα.
iFnγ il-2 TnFα
antigen rank Fold rise One-sided P-value antigen rank Fold rise One-sided P-value antigen rank Fold rise One-sided P-value
IE62-1 2.94 0.0000 IE62-2 3.38 0.0000 gB-1 2.29 0.0031
IE62-2 4.41 0.0000 IE62-1 2.08 0.0002 ORF9 1.61 0.0273
gB-2 2.30 0.0002 IE62-3 2.40 0.0004 IE62-2 1.79 0.0323
ORF9 4.02 0.0002 IE63 2.35 0.0005 gB-2 1.16 0.0448
gE-2 3.31 0.0007 ORF9 3.23 0.0019 ORF4 0.82 0.0516
IE62-3 2.79 0.0008 gB-2 2.27 0.0021 IE63 1.89 0.1128
IE63 4.31 0.0008 gE-2 2.94 0.0024 IE62-3 1.50 0.1214
gB-1 2.95 0.0012 gE-1 2.69 0.0031 ORF19-1 0.89 0.1623
ORF19-1 1.36 0.0017 ORF4 2.24 0.0097 gE-1 1.24 0.1666
gE-1 2.99 0.0021 gB-1 1.45 0.0210 IE62-1 1.49 0.1688
ORF10 1.75 0.0032 ORF19-1 1.38 0.0301 ORF10 0.83 0.2060
ORF29-2 1.78 0.0053 ORF29-1 1.71 0.0399 IE61 0.92 0.2584
ORF4 2.91 0.0071 ORF19-2 1.24 0.0895 gE-2 1.33 0.4204
ORF29-3 3.32 0.0107 ORF29-3 1.11 0.2375 ORF19-2 1.03 0.4324
ORF29-1 1.41 0.0223 ORF10 1.03 0.2899 ORF29-1 1.06 0.4459
ORF19-2 1.69 0.0487 ORF29-2 1.00 0.3047 ORF29-2 0.97 0.4459
IE61 1.17 0.0567 IE61 1.09 0.3166 ORF29-3 0.90 0.4459
P values were calculated using an Exact Wilcoxon’s Signed Rank Test.
largely influenced by the abundance of the ORF in the virion 
and modestly by the expression kinetics or function of the ORF 
(37). Similarly, in a herpes simplex virus (HSV)-1 study, majority 
of the T cell responses were weighted toward IE proteins and 
abundant virus polypeptides (38). VZV has a 125  kb genome 
with 71 ORFs (39). Therefore, to narrow our focus on antigens 
that may be critical for anti-VZV responses, the following 
selection criteria were considered: T cell reactivity of homologs 
expressed by related herpes viruses that lead to the activation of 
both CD4 and CD8 T cells, the temporal and kinetic expression 
of the proteins, and the abundance of the proteins on the virion. 
As such, 10 ORFs of the VZV genome that have previously been 
demonstrated to induce VZV-specific T cell-mediated responses 
(14, 18, 19, 22, 40–46) or stimulate T cell responses in related 
herpes viruses (38, 47–49), or that were abundant during pri-
mary VZV infection or latency (15, 50, 51), were selected for this 
study – gB, gE, IE61, IE62, IE63, ORF4, ORF9, ORF10, ORF19, 
and ORF29.
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a Boost in iFnγ, il-2, and TnFα Observed 
Following ZOsTaVaX Vaccination, in 
response to Broad VZV antigens
To investigate the cell-mediated responses induced by ZOSTAVAX, 
peptide pools spanning the VZV proteins listed earlier were used 
to stimulate whole blood acquired from human volunteers prior 
to ZOSTAVAX administration and 3–4  weeks postvaccination. 
Baseline levels of cytokines were detected upon antigen stimula-
tion of the prevaccination samples, demonstrating the presence 
of memory anti-VZV cells before vaccination (Figure 1). After 
ZOSTAVAX vaccination, we observed an increase in IFNγ, and 
IL-2 upon stimulation with all VZV antigens (Figure 1A). The 
increase in TNFα levels was not as robust as IFNγ and IL-2 
and was only observed upon stimulation with gB, gE, IE62, 
IE63, ORF9, and ORF29 (Figure  1A). While baseline levels of 
FigUre 1 | Boost in iFnγ, il-2, and TnFα following ZOsTaVaX vaccination. Whole blood was drawn from 21 subjects prior to and following ZOSTAVAX 
(3–4 weeks) vaccination. Within 2 h of blood draw, the specimen was stimulated with VZV peptide pools, VZV lysate (positive control), MRC5, and DMSO (negative 
controls) for 24 h. Plasma was then harvested and tested for the presence of (a) effector cytokines – IFNγ, IL-2, and TNFα; (B) pro-inflammatory cytokines – IL-1β 
and IL-10; and (c) anti-inflammatory cytokine IL-10, by using the Meso Scale Discovery kits. Each dot represents one subject. The geometric mean ± 95% 
confidence interval is shown for all data sets. Horizontal broken line denotes the lowest limit of detection for all cytokines.
pro-inflammatory responses (IL-1β and IL-6) were observed 
upon antigen stimulation prevaccination, vaccination with 
ZOSTAVAX did not boost their level of production (Figure 1B). 
Notably, a reduction in IL-10 levels was observed in peptide-
stimulated whole blood following vaccination with ZOSTAVAX 
(Figure 1C). For all VZV antigens tested, the levels of IL-4 and 
IL-5 were below the limit of detection and did not increase after 
vaccination with ZOSTAVAX (data not shown). Fold increases 
in IFNγ, IL-2, or TNFα production upon antigen stimulation are 
shown in Figures 2A–C. Statistical analyses of VZV antigen pools 
stimulating fold increase in cytokine responses are summarized 
in Table 1. Overall, the peptide pools that stimulated robust levels 
of IFNγ, IL-2, and TNFα were gB-1, gB-2, gE-1, gE-2, IE62-1, 
IE62-2, IE62-3, IE63, and ORF9. Henceforth, these peptide pools 
were used as antigenic stimuli for further T cell investigations via 
flow cytometry.
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Fold rise in Poly-Functional antigen-
specific cD4+ T cells Observed after 
Vaccination with ZOsTaVaX
We further expanded the whole blood stimulation data by phe-
notyping the antigen-specific T cell-mediated responses in these 
subjects. PBMC were stimulated with the above-selected peptide 
pools, VZV lysate, MRC5 lysate, vehicle (DMSO), or SEB and 
analyzed by flow cytometry for viable CD3+ T cells expressing 
either CD4 or CD8 (Figure  3A) and intracellular IFNγ, IL-2, 
and TNFα (Figure 3B). To identify activated CD4+ T cells, we 
also assessed for de novo expression of CD154 (CD40L) (52) 
(Figure  3B). A representative gating strategy from one indi-
vidual is shown in Figures 3A,B. In this subject, low frequency 
of memory CD4+ T cells eliciting each of the four functions 
upon stimulation with IE62 was detectable prior to vaccination 
(Figure 3A). Following vaccination, a boost in frequency of CD4+ 
T cells producing IFNγ+ increased by 8.6-fold, IL-2+ increased by 
5.5-fold, TNFα+ increased by 6.1-fold, and CD154+ increased by 
5.1-fold (Figure 3A).
To examine the full complexity of the CD4+ T cell response, 
we tested whether T cells producing IFNγ, IL-2, and TNFα 
and expressing CD154 were poly-functional. Boolean-gating 
algorithm was performed, which yielded 15 unique combina-
tions of the four measurements. Figure 3C shows IE63-specific 
CD4+ T cell responses from 21 subjects. For all antigens, a 
boost in the number of CD154+IFNγ+IL-2+TNFα+ (4+), and 
CD154−IFNγ+IL-2+TNFα+ (3+) was observed following vaccina-
tion (Figure 3C). However, minimal to no boost was observed 
for other functional combinations of cytokines, demonstrating 
that the functional heterogeneity was limited (Figure  3C). 
Henceforth, we only focused on 4+ (CD154+IFNγ+IL-2+TNFα+) 
and 3+ (CD154−IFNγ+IL-2+TNFα+) poly-functional CD4+ 
T cells and compared them to mono-functional cells (1+). By 
analyzing the fold rise in number of 4+ or 3+ antigen-specific 
CD4+ T cells as compared to mono-functional cells, we observed 
that IE63 induced the strongest poly-functional responses 
(Figures  4A,B). Statistical analyses ranking the five VZV anti-
gens in fold rise of 4+ poly-functional cells demonstrated that 
IE63 > IE62 > gB > VZV lysate > ORF9 > gE (Table 2). Similarly, 
statistical analyses ranking VZV antigens in the fold induction 
of 3+ poly-functional demonstrated that IE62 > ORF9 > gE > 
gB > IE63 > VZV lysate (Table 2) and are graphically shown in 
(Figure 4C).
Poly-Functional cD4+ T cells Produce 
More of each cytokine on a Per-cell Basis 
Than single Producers, and an increase in 
iFnγ is Observed after ZOsTaVaX 
Vaccination in response to ie63 and OrF9
We next questioned whether poly-functional CD4+ T cells dif-
fered in the amount of cytokine expressed on a per-cell basis 
as compared to mono-functional cells. To this end, geometric 
mean fluorescence intensity (GMFI) of IFNγ, IL-2, and TNFα 
was determined for each population. We found that for all 
antigens, prior to vaccination, 4+ and 3+ poly-functional CD4+ 
T cells produced up to 10 times more IFNγ (Figure  5), IL-2 
(Figure S1A in Supplementary Material), and TNFα (Figure S1B 
in Supplementary Material) than mono-functional T cells. The 
difference in expression of IFNγ was more significant between 
4+ and mono-functional cells (P values ≤0.001) than between 
3+ and mono-functional CD4+ T cells (Figure 5). The same is 
FigUre 2 | Fold rise in (a) iFnγ, (B) il-2, and (c) TnFα levels following ZOsTaVaX vaccination. The fold rise (post/pre) was calculated for each vaccinated 
subject. Graph shows the median ± interquartile range for all 21 subjects.
FigUre 3 | Poly-functional cD4+ T cells are boosted following ZOsTaVaX vaccination. PBMC were thawed and rested overnight before VZV 
antigen stimulation. One million PBMC/sample were stimulated with antigens for 5.5 h at 37°C/5% CO2, with brefeldin A and monensin added 30 min 
after the initial incubation. Cells were stained with Vividye, then fixed, permeabilized, and stained with antibodies to identify (a) CD3+ T cells, expressing 
either CD4 or CD8 that were producing (B) IFNγ, IL-2, TNFα, and CD154. Figure shows IE62-specific responses from one individual, and numbers on 
dot plots represent percentages of cells (DMSO subtracted) expressing each molecule. (c) Shows the heterogeneity of IE63-specific poly-functional CD4+ 
T cells for all 21 subjects as determined by Boolean-gating strategy. Each dot represents one subject, and the mean is shown for all phenotypes.
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true for IL-2 and TNFα cytokines (Figure S1 in Supplementary 
Material). We then assessed whether vaccination altered the 
cytokine expression profile of poly-functional T cells. Following 
vaccination, there was a statistically significant boost in the level 
of IFNγ production by poly-functional IE63- and ORF9-specific 
CD4+ T cells (P value <0.01). For other antigens, there was no 
FigUre 4 | hierarchy of VZV antigens stimulating poly-functional cD4+ T cells. (a) Grouped pie charts comparing the fold rise in poly-functional CD4+ T 
cells after stimulating PBMC with gB, gE, IE62, IE63, ORF9, and VZV lysate. Pie charts display 4+ functions (CD154+IFNγ+IL-2+TNFα+), 3+ functions 
(CD154−IFNγ+IL-2+TNFα+), or mono-functional cells. gB, gE, and IE62 were fractioned into multiple pools and poly-functional T cells were also assessed. Fold rise in 
the number of (B) 4+ (CD154+IFNγ+IL-2+TNFα+) or (c) 3+ (CD154−IFNγ+IL-2+TNFα+) CD4+ T cells for each VZV peptide pool. Each dot represents one subject, and 
the geometric mean ± 95% confidence interval is shown.
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statistical difference in IFNγ expression levels by poly-functional 
T cells, before and after vaccination. Similarly, there was no 
statistical difference in expression levels of IL-2 and TNFα 
by poly-functional T cells prior to and following vaccination. 
Notably, for all antigens, 4+ T cells found within the postvac-
cination population, produced the highest levels of IFNγ, IL-2, 
and TNFα with P values ≤0.0001 compared to mono-functional 
T cells.
FigUre 5 | Poly-functional cD4+ T cells express higher levels of iFnγ than mono-functional cells. Geometric mean fluorescence intensity (GMFI) of IFNγ 
was determined in 4+ (CD154+IFNγ+IL-2+TNFα+), 3+ (CD154−IFNγ+IL-2+TNFα+), and mono-functional antigen-specific CD4+ T cells prior to and following ZOSTAVAX 
vaccination. The mean ± SEM for the 21 subjects is shown for all data sets.
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Poly-Functional cD4+ T cells are Found 
Within the central and effector Memory 
Pool, and They Both express equivalent 
levels of cytokines
By examining the expression of CCR7, CD45RA, and CD45RO, 
the T cell compartment can be divided into the following memory 
subsets: central memory (TCM) (CCR7+CD45RA−CD45RO+), 
effector memory (TEM) (CCR7−CD45RA−CD45RO+), naive 
(CCR7+CD45RO−CD45RA+), and CD45RA+ effector memory 
(TEMRA) (CCR7−CD45RO−CD45RA+) (53–55). We therefore 
sought to investigate the phenotype of poly-functional CD4+ 
T cells responding to VZV antigens. To this end, PBMC from 
five subjects were stimulated with various peptide pools than 
stained for the expression of the CCR7, CD45RA, and CD45RO, 
concurrently with IFNγ, IL-2, TNFα, and CD154. These five 
subjects were chosen due to the availability of enough PBMC to 
carry out the entire set of analyses. Furthermore, these subjects 
showed similar phenotype and robust T cell responses to various 
antigens, and hence, they served as good representatives of the 21 
subjects. Figure 6A shows the expression of the memory markers 
by antigen-specific CD4+ T cells (red dots) over total CD3+ T cells 
(gray contours). We found a trend toward higher frequency of 4+ 
poly-functional cells TCM (51.6% ± 12.21, mean ± SEM) express-
ing CCR7+, as compared to 37.7% ± 11.34 CCR7− TEM cells. Of 
the CCR7+ population, 92.6% ±  9.7 was CD45RA−CD45RO+, 
while 96.3% ± 2.9 of the CCR7− subset was CD45RA−CD45RO+ 
(Figure 6A). Notably, neither naive nor TEMRA was found within 
the 4+ poly-functional CD4+ T cell population (Figure  6A). 
Functional assessment of IFNγ, IL-2, TNFα, and CD154 expres-
sion by TCM versus TEM 4+ poly-functional CD4+ T cells revealed 
that both memory populations produced equivalent levels of 
IFNγ, IL-2, and TNFα cytokines (Figure 6B).
Fold rise in central and effector Memory 
Poly-Functional OrF9-specific cD8+  
T cells Following ZOsTaVaX Vaccination
While we were able to detect CD4+ T cell responses after activa-
tion with gB, gE, IE62, IE63, and ORF9, detection of CD8+ T cell 
responses was limited to ORF9 activation, with 13 of 21 (62%) 
subjects responding. Figure  7A is representative data showing 
ORF9 stimulation of PBMC isolated before and after ZOSTAVAX 
vaccination in one subject. In addition to quantification of IFNγ, 
IL-2, and TNFα production by CD8+ T cells, we also assessed 
de novo expression of perforin by activated IFNγ+ T lymphocytes 
denoting cytotoxic T lymphocytes (56) (Figure  7A). Prior to 
vaccination, a low frequency of memory CD8+ T cells producing 
IFNγ, IL-2, and TNFα was detected (Figure 7A). Postvaccination, 
the median frequency of CD8+ T cells producing IFNγ+ increased 
by 2.8-fold, and TNFα+ increased by 4.9-fold (Figure 7A). The 
frequency of IL-2+ CD8+ T cells did not change after vaccination 
(Figure  7A). Notably, IFNγ+perforin+ CD8+ T cells were only 
observed after vaccination (Figure  7A). We observed that the 
FigUre 6 | Poly-functional cD4+ T cells display both TeM and TcM phenotypes. PBMC isolated from five subjects following ZOSTAVAX vaccination were 
thawed and rested overnight before VZV antigen stimulation. PBMC were stimulated with various VZV antigens for 5.5 h at 37°C/5% CO2, with brefeldin A and 
monensin added 30 min after the initial incubation. Cells were stained with Vividye, surface stained with fluorescent primary antibodies against CCR7, CD45RA, and 
CD45RO. After washing off excess antibodies, PBMC were fixed, permeabilized, and stained with fluorescent primary antibodies to identify T cells producing IFNγ, 
IL-2, TNFα, and CD154 as described in Figure 3. Boolean analysis was performed to identify poly-functional CD4+ T cells with 4+ functions. (a) CCR7, CD45RA, 
and CD45RO expressions of 4+ (CD154+IFNγ+IL-2+TNFα+) antigen-specific CD4+ T cells (red dots) overlayed on CD3+ T cells (gray contours). Numbers in dot plots 
represent percentage mean ± SEM for the five subjects. (B) The GMFI of IFNγ, IL-2, TNFα, and CD154 was assessed in both TCM (CCR7+CD45RA−CD45RO+) and 
TEM (CCR7−CD45RA−CD45RO+) 4+ antigen-specific CD4+ T cells.
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functional heterogeneity of the ORF9-specific CD8 T cells was 
quite diverse. The CD8+ T cells that had the highest fold increase 
(~20-fold) after vaccination were IFNγ+perforin+ cells followed by 
IFNγ+ cells (Figure 7B). Albeit rare, after ZOSTAVAX vaccination 
we were able to identify CD8+ T cells displaying all 4+ functions 
(IFNγ+IL-2+TNFα+perforin+) (Figure  7B). We also observed 
a threefold increase in the frequency of 3+ T cells expressing 
IFNγ, IL-2, and TNFα after vaccination (Figure 7B). Examining 
cytokine expression levels, both 4+ and 3+ CD8+ T cells prior to 
vaccination expressed low levels of IFNγ, IL-2, and TNFα that 
were comparable to mono-functional cells (Figure  7C). After 
vaccination, both 4+ and 3+ produced ~10-fold higher levels 
of IFNγ, IL-2, and TNFα than 1+ ORF9-specific CD8+ T cells 
(Figure  7C) and demonstrated a statistically significant boost 
(P ≥ 0.0001) in the expression of IFNγ, IL-2, and TNFα cytokines 
compared to prevaccination samples (Figure  7C). As with the 
CD4 T cell responses, we found a slightly higher proportion of 3+ 
poly-functional CD8+ T cells that were TCM (48.8% ± 11.2) versus 
43.4% ±  12.8 TEM. These data demonstrate that ORF9-specific 
CD8+ T cell populations were dominated by both TCM and TEM. 
We observed no difference in the expression levels of IFNγ, IL-2, 
and TNFα (Figure 7D).
FigUre 7 | OrF9-specific cD8+ T cells are poly-functional, produce more cytokines than mono-functional cells, and display both TeM and TcM 
phenotypes. (a) Representative gating strategy of PBMC prior to and following ZOSTAVAX vaccination that were stimulated with ORF9 peptide pool. Numbers in 
dot plots denotes percentages of CD8+ T cells producing IFNγ, IL-2, TNFα, and perforin. (B) Fold rise in the number of poly-functional CD8+ T cells demonstrating 
the heterogeneity of the T cell population. (c) The expression levels (GMFI) of IFNγ, IL-2, and TNFα by 4+ (IFNγ+IL-2+TNFα+perforin+), 3+ (IFNγ+IL-2+TNFα+), and 
mono-functional cells prior to and following ZOSTAVAX vaccination. (D) GMFI of IFNγ, IL-2, and TNFα was assessed in both ORF9-specific CD8+ TCM 
(CCR7+CD45RA−CD45RO+) and TEM (CCR7−CD45RA−CD45RO+).
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DiscUssiOn
Previous studies investigating T cell responses to ZOSTAVAX 
demonstrated an increase in IFNγ ELISPOT responses (9, 13, 
26) and effector memory T cells (9), thereby demonstrating 
that IFNγ-dependent T cell-mediated immune responses may 
contribute to ZOSTAVAX efficacy. A recent study by Laing et al. 
(28) surveyed the whole VZV genome for CD4+ reactivity by 
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assessing the proliferation of VZV-specific T cell lines from 12 
ZOSTAVAX recipients. They showed that responses to 42 VZV 
ORF were boosted upon vaccination (28). Indeed, we confirm 
their findings by reporting that cell-mediated responses against 
gB, gE, IE61, IE63, ORF4, ORF9, ORF10, ORF19, and ORF29 
were observed. Notably, the 10 VZV antigens investigated in our 
study were within the top 50% of the ORF reported by Laing et al. 
However, we did not want to introduce the bias of ORF expres-
sion and antigen presentation in vitro by the generation of T cell 
lines and hence used peptide stimulation ex vivo to get unbiased 
sampling of memory T cell responses. Between the two studies, 
the rank order for the magnitude of the responses to individual 
antigens differs as our approach of using peptides to assay T-cell 
responses avoids the bias of antigen expression, processing for 
presentation, and selective expansion of T cells. Irrespective of 
the methods used, the independent corroboration of similar VZV 
antigens gives credence to the observation.
Compelling evidence demonstrating that poly-functional T 
cells producing IFNγ, IL-2, and TNFα correlate with protection 
was shown using the mouse model of Leishmania major and 
Mycobacterium tuberculosis infection (57). Indeed, multifunc-
tional T cells have also been shown to be beneficial in human infec-
tions, such as HIV (58) and cytomegalovirus (59), and following 
vaccination with vaccinia (60, 61), hepatitis B, and tetanus toxoid 
(30). Among a diverse heterogeneous population of CD4+ T cells 
responding to various VZV antigens, we observed that the highest 
frequency of cells was CD154+IFNγ+IL-2+TNFα+ (4+ functions) 
and CD154−IFNγ+IL-2+TNFα+ (3+ functions) T cells. A previous 
study investigating CD4+ T cell responses after vaccination with 
HZ/gE subunit vaccine observed that the dominant population 
of T cells that increased following vaccination was CD154+IL-2+, 
and to a lesser extent IFNγ or TNFα expressing cells (62). By 
contrast, our study demonstrated a minimal increase in the 
frequency of gE-specific CD154+IL-2+ CD4 T cells and a higher 
frequency of 4+ CD4+ poly-functional T cells after vaccination. 
This discordance could be attributed to the use of different types 
of vaccines (subunit versus live attenuated). More importantly, 
the frequency of 4+ poly-functional CD4+ T cells was the highest 
among all phenotypes for the VZV antigens tested, demonstrat-
ing that this population is the dominant responder. In agreement 
with a previous study, we also observed poly-functional CD4+ T 
cells with three functions (IFNγ+IL-2+TNFα+) that were reactive 
to VZV lysate (11). However, we found that only 30% of CD4+ T 
cells responding to VZV lysate were poly-functional. While the 
larger proteins provided numerous epitopes for T cell activation, 
we found that length of the protein was not a factor as demon-
strated by robust CD4+ reactivity to ORF9 (302 amino acids) and 
IE63 (278 amino acids).
Prior investigations have demonstrated a skewing of anti-VZV 
T cell responses toward CD4+ T cells (11, 14, 15, 18–20, 22, 23, 28, 
41, 43–45, 63), with few VZV-specific CD8+ T cells reported (9, 14, 
17, 20, 44, 63). By following standard intracellular cytokine stain-
ing (ICS) protocols, the frequency of VZV-specific CD8+ T cells 
was shown to be below the limit of detection (17, 21, 62). Therefore, 
to detect VZV-specific CD8+ T cells, rigorous activation protocols 
have been utilized such as overnight stimulation of PBMC with 
live VZV (9) and the activation of PBMC for several days with 
either VZV lysate or peptides prior (17, 20, 44, 63). The extended 
incubation of PBMC with VZV facilitates the processing and 
presentation of antigen to CD8+ T cells and generation of de novo 
antigen-specific T cells. However, previous studies that stimulated 
PBMC with peptides which do not require processing were unable 
to detect antigen-specific CD8+ T cells (17). In agreement with the 
previous studies, we found that the frequency of gB, gE, IE62, and 
IE63-specific CD8+ T cells was below the limit of detection via 
ICS. Surprisingly, we were able to detect ex vivo poly-functional 
CD8+ T cells that were reactive to ORF9 in 62% of the subjects. 
Whether these cells play a role in cytolysis of virus-infected cells 
remains to be elucidated; however, their expression of IFNγ, IL-2, 
TNFα, and perforin suggests that they are indeed armed for this 
function. Moreover, the induction of poly-functional CD8+ T cells 
suggests that ZOSTAVAX replicates in vivo.
The benefit of poly-functional T cells in protection against 
pathogens has been attributed by their: (a) ability to express 
higher levels of IFNγ on a per-cell basis than other populations 
(49, 57, 60, 64); (b) enhanced cytotoxicity due to secretion of both 
IFNγ and TNFα (65, 66); and (c) high IL-2-mediated proliferative 
capacity (67). Indeed, our investigations demonstrate that on a 
per-cell basis VZV-specific poly-functional CD4+ and CD8+ T 
cells produce 10-fold more IFNγ, IL-2, and TNFα than mono-
functional T cells. A marked increase in IFNγ expression by poly-
functional IE63- and ORF9-specific CD4+ T cells was observed 
after vaccination. The difference in expression of IFNγ, IL-2, and 
TNFα cytokines was more significant between 4+ and mono-
functional cells than between 3+ and mono-functional CD4+ T 
cells. After ZOSTAVAX vaccination, a marked increase in IFNγ, 
IL-2, and TNFα cytokine expression levels was also observed by 
CD8+ poly-functional T cells.
Given that no other reports had detected ex vivo antigen-
specific CD8+ T cells without extended T cell culture, our 
identification of ORF9-specific CD8+ T cells was quite surprising. 
Interestingly, crossreactive human CD8+ T cells that recognize 
conserved epitopes among related herpes viruses have been 
reported (68). The authors found a CD8+ T cell epitope from 
VZV ribonuclease reductase subunit 2 protein (ORF18) that 
was homologous to HSV and Epstein–Barr virus (68). However, 
ZOSTAVAX vaccination was not reported to stimulate/enhance 
ORF18 epitope-specific CD8+ T cell responses in majority of 
the subjects (68). Following the same rationale, we questioned 
whether ORF9-specific CD8+ T cell responses observed in our 
study were derived from crossreactivity with HSV. ORF9 protein 
is an ortholog of HSV VP22 protein that shares 25% identity and 
34% similarity (69) and is the most abundant VZV transcript 
during primary infection (51). VP22 is encoded by UL49 gene, 
and as such, ORF9 gene is 43% identical and 56% similar to 
UL49 (69). Interestingly, poly-functional UL49-specific CD8+ T 
cells in HSV-infected individuals have been shown to produce 
IFNγ, IL-2, and TNFα (49). Therefore, to assess this crossreactive 
possibility, PBMC from HSV-positive donors were stimulated 
with UL49 and ORF9 peptide pools, and ICS performed to 
detect IFNγ, IL-2, and TNFα production by CD4+ and CD8+ T 
cells. While UL49-specific CD4+ and CD8+ T cells producing 
IFNγ, IL-2, and TNFα could be detected, we could not detect 
ORF9-specific T cells (data not shown). In a converse experiment, 
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ZOSTAVAX vaccines with ORF9-specific CD8+ and CD4+ T cell 
responses were stimulated with UL49 peptide pool. Notably, no 
UL49-specific CD8+ responses were detected, whereas two of the 
five subjects showed UL49-specific CD4+ T cell responses. The 
latter CD4+ T cell results are confounded by the fact that we did 
not type our ZOSTAVAX vaccines for HSV exposure. These data 
led us to infer that the ORF9-specific CD8+ T cells responses were 
not due to crossreactivity to HSV.
In conclusion, our evaluation of VZV-specific T cell-mediated 
immune responses demonstrated that a wide repertoire of both 
TCM and TEM poly-functional CD4+ T cells expressing IFNγ, 
IL-2, TNFα, and CD154 were boosted following ZOSTAVAX 
vaccination. Poly-functional IE63-specific CD4+ T cells were the 
dominant responders as evidenced by a statistically significant 
boost in cell frequency and the level of IFNγ produced on a per-
cell basis. A novel ORF9-specific poly-functional CD8+ T cells 
was also boosted upon vaccination, expressed higher levels of 
cytokines following vaccination, and was found to belong to both 
TCM and TEM population.
aUThOr cOnTriBUTiOns
Conceived and designed of the experiments: JS, KC, SD, DK, DC, 
and KV. Performed the experiments: JS, KC, and SD. Analyzed 
or interpreted the data: JS, KC, SD, JA, and KV. Wrote the manu-
script: JS and KV.
acKnOWleDgMenTs
We would like to thank all the subjects who participated in this 
study. We would also like to thank Drs. Todd M. Gierahn, Paula 
W. Annunziato, Zoran Popmihajlov, and John Konz for critically 
reviewing the manuscript.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/
fimmu.2015.00553
reFerences
1. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella 
zoster virus infection: clinical features, molecular pathogenesis of 
disease, and latency. Neurol Clin (2008) 26:675–697,viii. doi:10.1016/j.
ncl.2008.03.011 
2. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new 
hypothesis. Proc R Soc Med (1965) 58:9–20. 
3. Kumagai T, Chiba Y, Wataya Y, Hanazono H, Chiba S, Nakao T. Development 
and characteristics of the cellular immune response to infection with varicel-
la-zoster virus. J Infect Dis (1980) 141:7–13. doi:10.1093/infdis/141.1.7 
4. Arvin AM, Koropchak CM, Williams BR, Grumet FC, Foung SK. Early 
immune response in healthy and immunocompromised subjects with primary 
varicella-zoster virus infection. J Infect Dis (1986) 154:422–9. doi:10.1093/
infdis/154.3.422 
5. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract (1975) 25:571–5. 
6. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune 
responses to varicella-zoster in the aged. Arch Intern Med (1982) 142:291–3. 
doi:10.1001/archinte.1982.00340150091017 
7. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O’Malley PM, Underwood R, 
et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 
(1992) 166:1153–6. doi:10.1093/infdis/166.5.1153 
8. Kost RG, Straus SE. Postherpetic neuralgia – pathogenesis, treatment, and pre-
vention. N Engl J Med (1996) 335:32–42. doi:10.1056/NEJM199607043350107 
9. Patterson-Bartlett J, Levin MJ, Lang N, Schodel FP, Vessey R, Weinberg 
A. Phenotypic and functional characterization of ex vivo T cell responses 
to the live attenuated herpes zoster vaccine. Vaccine (2007) 25:7087–93. 
doi:10.1016/j.vaccine.2007.07.051 
10. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A pop-
ulation-based study of the incidence and complication rates of herpes 
zoster before zoster vaccine introduction. Mayo Clin Proc (2007) 82:1341–9. 
doi:10.4065/82.11.1341 
11. Schub D, Janssen E, Leyking S, Sester U, Assmann G, Hennes P, et  al. 
Altered phenotype and functionality of varicella zoster virus-specific cellular 
immunity in individuals with active infection. J Infect Dis (2015) 211:600–12. 
doi:10.1093/infdis/jiu500 
12. Miller AE. Selective decline in cellular immune response to varicella-zoster in 
the elderly. Neurology (1980) 30:582–7. doi:10.1212/WNL.30.6.582 
13. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward 
AR, et  al. Varicella-zoster virus-specific immune responses in elderly 
recipients of a herpes zoster vaccine. J Infect Dis (2008) 197:825–35. 
doi:10.1086/528696 
14. Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, Kinchington P, et al. 
Equivalent recognition of a varicella-zoster virus immediate early protein 
(IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or 
CD8+ phenotype. J Immunol (1991) 146:257–64. 
15. Sadzot-Delvaux C, Arvin AM, Rentier B. Varicella-zoster virus IE63, a virion 
component expressed during latency and acute infection, elicits humoral and 
cellular immunity. J Infect Dis (1998) 178(Suppl 1):S43–7. doi:10.1086/514259 
16. Abendroth A, Arvin A. Varicella-zoster virus immune evasion. Immunol Rev 
(1999) 168:143–56. doi:10.1111/j.1600-065X.1999.tb01289.x 
17. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, Arvin AM. Identification 
of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of vari-
cella-zoster virus, and evaluation of frequency of CD8+ T cell response to 
IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis (2003) 
188:40–52. doi:10.1086/375828 
18. Jones L, Black AP, Malavige GN, Ogg GS. Phenotypic analysis of human CD4+ 
T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur 
J Immunol (2007) 37:3393–403. doi:10.1002/eji.200737648 
19. Malavige GN, Jones L, Black AP, Ogg GS. Varicella zoster virus glycoprotein 
E-specific CD4+ T cells show evidence of recent activation and effector 
differentiation, consistent with frequent exposure to replicative cycle 
antigens in healthy immune donors. Clin Exp Immunol (2008) 152:522–31. 
doi:10.1111/j.1365-2249.2008.03633.x 
20. Kleemann P, Distler E, Wagner EM, Thomas S, Klobuch S, Aue S, et  al. 
Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and 
CD8+ T cells reconstituting during zoster after allogeneic transplantation. 
Haematologica (2012) 97:874–82. doi:10.3324/haematol.2011.052597 
21. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. Frequencies of 
memory T cells specific for varicella-zoster virus, herpes simplex virus, and 
cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 
(2000) 181:859–66. doi:10.1086/315347 
22. Jones L, Black AP, Malavige GN, Ogg GS. Persistent high frequencies of vari-
cella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. 
J Virol (2006) 80:9772–8. doi:10.1128/JVI.00564-06 
23. Malavige GN, Jones L, Black AP, Ogg GS. Rapid effector function of vari-
cella-zoster virus glycoprotein I-specific CD4+ T cells many decades after 
primary infection. J Infect Dis (2007) 195:660–4. doi:10.1086/511274 
24. Schmader KE, Levin MJ, Gnann JW Jr, Mcneil SA, Vesikari T, Betts RF, et al. 
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 
years. Clin Infect Dis (2012) 54:922–8. doi:10.1093/cid/cir970 
25. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. 
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. 
N Engl J Med (2005) 352:2271–84. doi:10.1056/NEJMoa051016 
October 2015 | Volume 6 | Article 55314
Sei et al. Zostavax boosts polyfunctional T-cells
Frontiers in Immunology | www.frontiersin.org
26. Vermeulen JN, Lange JM, Tyring SK, Peters PH, Nunez M, Poland G, et al. 
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine 
in healthy adults >/=60 years of age. Vaccine (2012) 30:904–10. doi:10.1016/j.
vaccine.2011.11.096 
27. Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, et  al. Fold rise in 
antibody titers by measured by glycoprotein-based enzyme-linked immuno-
sorbent assay is an excellent correlate of protection for a herpes zoster vaccine, 
demonstrated via the vaccine efficacy curve. J Infect Dis (2014) 210:1573–81. 
doi:10.1093/infdis/jiu279 
28. Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, Magaret A, et al. Zoster 
vaccination increases the breadth of CD4+ T cells responsive to varicella 
zoster virus. J Infect Dis (2015) 212(7):1022–31. doi:10.1093/infdis/jiv164 
29. Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi 
K. Comparison of the complete DNA sequences of the Oka varicella 
vaccine and its parental virus. J Virol (2002) 76:11447–59. doi:10.1128/
JVI.76.22.11447-11459.2002 
30. De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, Moser S, et al. Vaccination 
in humans generates broad T cell cytokine responses. J Immunol (2004) 
173:5372–80. doi:10.4049/jimmunol.173.9.5372 
31. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, et  al. 
Optimization and validation of an 8-color intracellular cytokine staining (ICS) 
assay to quantify antigen-specific T cells induced by vaccination. J Immunol 
Methods (2007) 323:39–54. doi:10.1016/j.jim.2007.03.002 
32. Lovelace P, Maecker HT. Multiparameter intracellular cytokine staining. 
Methods Mol Biol (2011) 699:165–78. doi:10.1007/978-1-61737-950-5_8 
33. De Rosa SC, Carter DK, Mcelrath MJ. OMIP-014: validated multifunctional 
characterization of antigen-specific human T cells by intracellular cytokine 
staining. Cytometry A (2012) 81:1019–21. doi:10.1002/cyto.a.22218 
34. Lelic A, Verschoor CP, Ventresca M, Parsons R, Evelegh C, Bowdish D, et al. 
The polyfunctionality of human memory CD8+ T cells elicited by acute 
and chronic virus infections is not influenced by age. PLoS Pathog (2012) 
8:e1003076. doi:10.1371/journal.ppat.1003076 
35. Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, Fernandez VR, et al. 
Enhanced rates and magnitude of immune responses detected against an HIV 
vaccine: effect of using an optimized process for isolating PBMC. AIDS Res 
Hum Retroviruses (2007) 23:86–92. doi:10.1089/aid.2006.0129 
36. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cy-
tometric complex multivariate datasets. Cytometry A (2011) 79:167–74. 
doi:10.1002/cyto.a.21015 
37. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et  al. 
Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells 
dominate the memory compartments of exposed subjects. J Exp Med (2005) 
202:673–85. doi:10.1084/jem.20050882 
38. Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, et  al. Cross-
presentation and genome-wide screening reveal candidate T cells antigens 
for a herpes simplex virus type 1 vaccine. J Clin Invest (2012) 122:654–73. 
doi:10.1172/JCI60556 
39. Abendroth A, Arvin AM, Moffat JF. Varicella-zoster virus. Preface. Curr Top 
Microbiol Immunol (2010) 342:v–vi. doi:10.1007/82_2010_41
40. Arvin AM, Kinney-Thomas E, Shriver K, Grose C, Koropchak CM, Scranton 
E, et al. Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and 
gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 
137:1346–51. 
41. Giller RH, Winistorfer S, Grose C. Cellular and humoral immunity to varicella 
zoster virus glycoproteins in immune and susceptible human subjects. J Infect 
Dis (1989) 160:919–28. doi:10.1093/infdis/160.6.919 
42. Hayward A, Giller R, Levin M. Phenotype, cytotoxic, and helper functions of 
T cells from varicella zoster virus stimulated cultures of human lymphocytes. 
Viral Immunol (1989) 2:175–84. doi:10.1089/vim.1989.2.175 
43. Bergen RE, Sharp M, Sanchez A, Judd AK, Arvin AM. Human T cells 
recognize multiple epitopes of an immediate early/tegument protein (IE62) 
and glycoprotein I of varicella zoster virus. Viral Immunol (1991) 4:151–66. 
doi:10.1089/vim.1991.4.151 
44. Arvin AM, Sharp M, Moir M, Kinchington PR, Sadeghi-Zadeh M, Ruyechan 
WT, et al. Memory cytotoxic T cell responses to viral tegument and regulatory 
proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster 
virus. Viral Immunol (2002) 15:507–16. doi:10.1089/088282402760312377 
45. Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando 
N, et  al. IE63-specific T-cell responses associate with control of subclinical 
varicella zoster virus reactivation in individuals with malignancies. Br J Cancer 
(2010) 102:727–30. doi:10.1038/sj.bjc.6605542 
46. Meyer C, Kerns A, Haberthur K, Dewane J, Walker J, Gray W, et al. Attenuation 
of the adaptive immune response in rhesus macaques infected with simian 
varicella virus lacking open reading frame 61. J Virol (2013) 87:2151–63. 
doi:10.1128/JVI.02369-12 
47. Koelle DM, Frank JM, Johnson ML, Kwok WW. Recognition of herpes simplex 
virus type 2 tegument proteins by CD4 T cells infiltrating human genital 
herpes lesions. J Virol (1998) 72:7476–83. 
48. Hosken N, Mcgowan P, Meier A, Koelle DM, Sleath P, Wagener F, et  al. 
Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins 
among persons with genital herpes. J Virol (2006) 80:5509–15. doi:10.1128/
JVI.02659-05 
49. Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, De Rosa SC, 
et  al. Diversity in CD8(+) T cell function and epitope breadth among 
persons with genital herpes. J Clin Immunol (2010) 30:703–22. doi:10.1007/
s10875-010-9441-2 
50. Sadzot-Delvaux C, Kinchington PR, Debrus S, Rentier B, Arvin AM. 
Recognition of the latency-associated immediate early protein IE63 of 
varicella-zoster virus by human memory T lymphocytes. J Immunol (1997) 
159:2802–6. 
51. Cohrs RJ, Hurley MP, Gilden DH. Array analysis of viral gene transcription 
during lytic infection of cells in tissue culture with varicella-zoster virus. J 
Virol (2003) 77:11718–32. doi:10.1128/JVI.77.21.11718-11732.2003 
52. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-spe-
cific CD4+ T cells with diverse cytokine profiles. Nat Med (2005) 11:1113–7. 
doi:10.1038/nm1293 
53. Michie CA, Mclean A, Alcock C, Beverley PC. Lifespan of human lym-
phocyte subsets defined by CD45 isoforms. Nature (1992) 360:264–5. 
doi:10.1038/360264a0 
54. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of mem-
ory T lymphocytes with distinct homing potentials and effector functions. 
Nature (1999) 401:708–12. doi:10.1038/44385 
55. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. 
Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 
(2001) 410:106–11. doi:10.1038/35065118 
56. Hersperger AR, Makedonas G, Betts MR. Flow cytometric detection of 
perforin upregulation in human CD8 T cells. Cytometry A (2008) 73:1050–7. 
doi:10.1002/cyto.a.20596 
57. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. 
Multifunctional TH1 cells define a correlate of vaccine-mediated protec-
tion against Leishmania major. Nat Med (2007) 13:843–50. doi:10.1038/
nm1592 
58. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham 
J, et  al. HIV nonprogressors preferentially maintain highly functional 
HIV-specific CD8+ T cells. Blood (2006) 107:4781–9. doi:10.1182/
blood-2005-12-4818 
59. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, et al. 
Acquisition of direct antiviral effector functions by CMV-specific CD4+ 
T lymphocytes with cellular maturation. J Exp Med (2006) 203:2865–77. 
doi:10.1084/jem.20052246 
60. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, et al. 
Immunization with vaccinia virus induces polyfunctional and phenotyp-
ically distinctive CD8(+) T cell responses. J Exp Med (2007) 204:1405–16. 
doi:10.1084/jem.20062363 
61. Miller JD, Van Der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust 
D, et  al. Human effector and memory CD8+ T cell responses to smallpox 
and yellow fever vaccines. Immunity (2008) 28:710–22. doi:10.1016/j.
immuni.2008.02.020 
62. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeliere P, Vassilev V, 
Ledent E, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity 
of a varicella zoster glycoprotein e subunit vaccine candidate in young and 
older adults. J Infect Dis (2012) 206:1280–90. doi:10.1093/infdis/jis497 
63. Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 
(1992) 166(Suppl 1):S35–41. doi:10.1093/infdis/166.Supplement_1.S35 
October 2015 | Volume 6 | Article 55315
Sei et al. Zostavax boosts polyfunctional T-cells
Frontiers in Immunology | www.frontiersin.org
64. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. 
Multiple-cytokine-producing antiviral CD4 T cells are functionally superior 
to single-cytokine-producing cells. J Virol (2007) 81:8468–76. doi:10.1128/
JVI.00228-07 
65. Bogdan C, Moll H, Solbach W, Rollinghoff M. Tumor necrosis factor-alpha 
in combination with interferon-gamma, but not with interleukin 4 activates 
murine macrophages for elimination of Leishmania major amastigotes. Eur 
J Immunol (1990) 20:1131–5. doi:10.1002/eji.1830200528 
66. Liew FY, Li Y, Millott S. Tumor necrosis factor-alpha synergizes with IFN-
gamma in mediating killing of Leishmania major through the induction of 
nitric oxide. J Immunol (1990) 145:4306–10. 
67. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes 
from normal human bone marrows. Science (1976) 193:1007–8. doi:10.1126/
science.181845 
68. Chiu C, Mccausland M, Sidney J, Duh FM, Rouphael N, Mehta A, et  al. 
Broadly reactive human CD8 T cells that recognize an epitope conserved 
between VZV, HSV and EBV. PLoS Pathog (2014) 10:e1004008. doi:10.1371/
journal.ppat.1004008 
69. Cilloniz C, Jackson W, Grose C, Czechowski D, Hay J, Ruyechan WT. The 
varicella-zoster virus (VZV) ORF9 protein interacts with the IE62 major VZV 
transactivator. J Virol (2007) 81:761–74. doi:10.1128/JVI.01274-06 
Conflict of Interest Statement: All authors are employees of Merck & Co., Inc. and 
may hold stock in the company as a part of their annual compensation.
Copyright © 2015 Sei, Cox, Dubey, Antonello, Krah, Casimiro and Vora. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
